Apellis Pharmaceuticals, Inc. has experienced a mixed financial outcome for Q4 2025, posting declining revenues of $199.91 million, down 5.9% year-over-year, despite achieving a total revenue of $1 billion for the year. The company reported an EPS of $0.47, reversing last year's losses, yet shares have plummeted by 20.8%, contrasting starkly with industry growth. As Apellis faces challenges including high operating expenses and significant convertible debt, it aims to leverage its strong payer coverage and ongoing clinical studies for future growth.
“Wedbush · lowered · price target on Apellis · $18 from $20”
“Wedbush · keeps · rating on Apellis shares · Neutral”
“Apellis · anticipated · Q4 report · largely as anticipated”
“Apellis Pharmaceuticals · has · year-to-date total return decline · -17%”
“Apellis Pharmaceuticals · has · 1-year total return decline · -18.6%”
“Apellis Pharmaceuticals · has · peer average P/E ratio · 40x”
“Apellis Pharmaceuticals, Inc. · characterizes · 2025 · foundational year of disciplined execution”
“Apellis Pharmaceuticals · reported · fourth-quarter 2025 loss · 47 cents per share”
“Apellis Pharmaceuticals · reported · Zacks Consensus Estimate loss · 39 cents”
“Apellis Pharmaceuticals · incurred · loss in year-ago quarter · 29 cents”
“Apellis · delivered · commercial vials and samples of Syfovre · more than 89,000 commercial vials and nearly 13,000 samples”
“Shares of Apellis · have plunged · 20.8% · against the industry’s 22.2% growth”
